Leukemia & Lymphoma
Specialty Channel

Featured Article
Long-term follow-up from the FoRT study shows that the optimal RT dose for patients with indolent NHL and histologic FL or MZL is 24 Gy in 12 fractions.
Patients with NHL with intermediate risk for FN maintain that risk even with pegfilgrastim prophylaxis, according to research presented at the NCCN Annual Conference.
Study findings have led experts to suggest that comorbidities in patients with non-Hodgkin’s lymphoma do not present randomly, but have distinct patterns, according to research presented at the NCCN…
The current protocol for monitoring the response to chemo in patients with ALL is a bone marrow biopsy, but a better one may exist, according to data presented at the NCCN Annual Conference.
Study findings lead experts to suggest that the prevalence of DLBCL and FL will likely rise in the United States and Europe, according to research presented at the NCCN Annual Conference.
At the virtual Great Debates & Updates in Hematologic Malignancies, Jonathon Cohen, MD, presented standard treatment regiments and novel agents for the treatment of MCL.
The FDA has approved lisocabtagene maraleucel, a new CAR-T therapy, for the treatment of adults with relapsed or refractory large B-cell lymphoma after at least 2 lines of systemic therapy.
The FDA granted accelerated approval to umbralisib for the treatment of adults with relapsed/refractory FL or MZL.
In a study of adults transplanted for high-risk AML or MDS, an intensified RIC regimen did not improve outcomes, regardless of pretransplant MRD status.

News

Long-term follow-up from the FoRT study shows that the optimal RT dose for patients with indolent NHL and histologic FL or MZL is 24 Gy in 12 fractions.
Patients with NHL with intermediate risk for FN maintain that risk even with pegfilgrastim prophylaxis, according to research presented at the NCCN Annual Conference.
Study findings have led experts to suggest that comorbidities in patients with non-Hodgkin’s lymphoma do not present randomly, but have distinct patterns, according to research presented at the NCCN…
The current protocol for monitoring the response to chemo in patients with ALL is a bone marrow biopsy, but a better one may exist, according to data presented at the NCCN Annual Conference.

Interactive Features

True or False: Brentuximab vedotin combined with chemotherapy is significantly more effective than chemotherapy alone in patients with CD30-positive peripheral T-cell lymphomas.
True or False: In the phase 2 ZUMA-2 clinical trial, anti-CD19 CAR-T therapy with KTE-X19 yielded no benefit in the majority of patients with relapsed or refractory MCL.
True or False: Rituximab plus bendamustine administered before autologous SCT in patients with MCL led to very low rates of durable remission in a pooled analysis by Merryman et al.
True or False: Bortezomib maintenance therapy after transplantation yields no positive effect in young patients with MCL.
Stay in the know.
OncNet Newsletter